$-0.14
(Market cap
$478 Mln
Revenue (TTM)
$47 Mln
P/E Ratio
--
P/B Ratio
4.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
153,580,035
10 Years Aggregate
CFO
$-812.95 Mln
EBITDA
$-1,259.00 Mln
Net Profit
$-1,189.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| 54.1 | 17.9 | -11.5 | 18.4 | -28.8 | -45.5 | -16.1 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| 61.4 | -87.2 | 14.2 | -66.6 | -62.1 | 136.8 | 30.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
|
3.2 | 477.6 | 47.0 | -74.0 | -154.6 | -111.6 | -- | 4.3 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 72.1 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.4 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 600.7 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Editas Medicine (EDIT)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead... program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Dr. Gilmore O'Neill M.D.
-
President, CEO & Director
Dr. Gilmore O'Neill M.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Editas Medicine (EDIT)
What is the current share price of Editas Medicine Inc (EDIT) Today?
The share price of Editas Medicine Inc (EDIT) is $3.16 (NASDAQ) as of 28-Aug-2026 16:02 EDT. Editas Medicine Inc (EDIT) has given a return of -28.84% in the last 3 years.
What is the current PB & PE ratio of Editas Medicine Inc (EDIT)?
Since, TTM earnings of Editas Medicine Inc (EDIT) is negative, P/E ratio is not available.
The P/B ratio of Editas Medicine Inc (EDIT) is 4.26 times as on 21-Aug-2026, a 20 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.14 |
6.67 |
2024 |
-0.44 |
0.78 |
2023 |
-5.40 |
2.37 |
2022 |
-2.99 |
1.69 |
2021 |
-9.80 |
3.28 |
What is the 52 Week High and Low of Editas Medicine Inc (EDIT)?
The 52-week high and low of Editas Medicine Inc (EDIT) are Rs 4.54 and Rs 1.66 as of 30-Aug-2026.
What is the market cap of Editas Medicine Inc (EDIT)?
Editas Medicine Inc (EDIT) has a market capitalisation of $ 478 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Editas Medicine Inc (EDIT)?
Before investing in Editas Medicine Inc (EDIT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.